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OBJECTIVES This study sought to investigate whether the anatomical location of the disease carries
prognostic implications in patients undergoing drug-eluting stent (DES) implantation for the
left main coronary artery (LMCA) stenosis.
BACKGROUND Liberal use of DES, compared with a bare metal stent (BMS), has resulted in an improved
outcome in patients undergoing LMCA intervention. However, the overall event rate in this
subset of patients remains high, and alternative tools to risk-stratify this population beyond
conventional surgical risk status would be desirable.
METHODS From April 2002 to June 2004, 130 patients received DES as part of the percutaneous
intervention for LMCA stenoses in our institution. Distal LMCA disease (DLMD) was
present in 94 patients. They were at higher surgical risk and presented with a greater coronary
disease extent compared with patients without DLMD.
RESULTS After a median of 587 days (range 368 to 1,179 days), the cumulative incidence of major
adverse cardiac events (MACE) was significantly higher in patients with DLMD at 30%
versus 11% in those without DLMD (hazard ratio [HR] 3.42, 95% confidence interval [CI]
1.34 to 9.7; p  0.007), mainly driven by the different rate of target vessel revascularization
(13% and 3%; HR 6, 95% CI 1.2 to 29; p 0.02). After adjustment for confounders, DLMD
(HR 2.79,95% CI 1.17 to 8.9; p  0.032) and surgical risk status (HR 2.18,95% CI 1.06 to
4.5; p  0.038) remained independent and complementary predictors of MACE.
CONCLUSIONS Distal LMCA disease carries independent prognostic implications, and it may help in
selecting the most appropriate patient subset for LMCA intervention beyond the conven-
tional surgical risk status in the DES era. (J Am Coll Cardiol 2006;47:1530–7) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066the American College of Cardiology Foundation
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loutine implantation of drug-eluting stents (DES), by
educing the need for target vessel revascularization (TVR)
nd angiographic restenosis, recently has been shown to
avorably affect outcome compared with bare-metal stents
BMS) in patients undergoing percutaneous left main cor-
nary artery (LMCA) intervention (1–3). However, the rate
f major cardiovascular events in the DES era remains high
n the first series of patients reported (1,3). Catheter-based
MCA treatment is today mainly reserved for poor surgical
andidates, which may at least partially explain the high rate
f adverse events observed in this patient population. This
ypothesis is based on the ability of surgical risk scores to
From the Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands.p
Manuscript received October 2, 2005; revised manuscript received October 28,
005, accepted November 8, 2005.redict both short-term and long-term outcomes in this
ubset of patients (1,4).
The identification of novel independent predictors of
utcome beyond surgical risk status would further expand
ur capability to risk-stratify this patient population.
In particular, a clinical or angiographic parameter able to
ifferentiate outcomes between percutaneous LMCA treat-
ent and surgical revascularization would be highly desir-
ble. This might help in selecting the appropriate subset of
atients with LMCA disease in whom catheter-based
reatment would be indicated, independent of surgical risk
tatus (5).
Observational studies in the BMS era identified the distal
ocation of the disease within the LMCA anatomy as a
ossible determinant of restenosis in patients undergoing
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April 18, 2006:1530–7 Prognostic Impact of Distal Left Main Diseaseercutaneous treatment of the LMCA (6). However, other
nvestigators have not confirmed this observation (7,8), and
hether this holds true in the DES era remains largely
nknown.
The treatment of distal left main disease (DLMD) is
ffset by the need to handle the bifurcation between LMCA
nd the main proximal left coronary branches. The treat-
ent of such a lesion, even with the use of DES, may
emain challenging (9).
Therefore, the purpose of the present study was to
nvestigate the clinical and angiographic outcomes of
LMD treatment in patients undergoing percutaneous
evascularization in the DES era.
ETHODS
tudy design and patient population. Since April 16,
002, sirolimus-eluting stent (SES) implantation (Cypher,
ohnson & Johnson-Cordis unit, Warren, New Jersey) have
een used as a default strategy for every percutaneous coronary
ntervention at our institution as part of the Rapamycin-
luting Stent Evaluated At Rotterdam Cardiology Hospital
RESEARCH) registry. From the first quarter of 2003,
aclitaxel-eluting stents (Taxus, Boston Scientific, Natick,
assachusetts) became commercially available, replacing
ES as the stent of choice in every percutaneous coronary
ntervention, as part of the Taxus-Stent Evaluated At
otterdam Cardiology Hospital (T-SEARCH) registry. As
policy, all elective patients presenting with significant
50% by visual estimation) LMCA disease referred to our
nstitution for coronary revascularization are evaluated both
y interventional cardiologists and by cardiac surgeons, and
he decision to opt for percutaneous coronary intervention or
urgery is reached by consensus, as previously described (1).
From April 16, 2002, to June 28, 2004, a total of 130
onsecutive patients were treated exclusively with one or
ore DES in the LMCA as part of an elective or nonelec-
ive revascularization procedure and constitute the patient
opulation of the present report. Fifty-five patients in the
rst cohort received exclusively SES, which were avail-
ble at that time in diameters from 2.25 to 3.00 mm,
hereas in the next group of 75 patients, paclitaxel-
luting stents—available in diameters from 2.25 to 3.5
Abbreviations and Acronyms
BMS  bare-metal stent
DES  drug-eluting stent
DLMD  distal left main disease
LMCA  left main coronary artery
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal luminal diameter
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarction
TVR  target vessel revascularizationm—were implanted.
a
TTo stratify the study population into high surgical risk
nd low surgical risk groups, the Parsonnet surgical risk
core was calculated for each patient (10). A score of 15
as used to identify patients at high risk as previously
uggested (4,11). Protected LMCA segment was defined by
he presence of at least one patent arterial or venous conduit
o at least one left coronary segment. Nonelective treatment
as defined as a procedure carried out on referral before the
eginning of the next working day (12).
This protocol was approved by the hospital ethics com-
ittee and is in accordance with the Declaration of Hel-
inki. Written informed consent was obtained from every
atient.
rocedures and post-intervention medications. All inter-
entions were performed according to current standard
uidelines. The final interventional strategy, including the
se of glycoprotein IIb/IIIa inhibitors, was entirely left to
he discretion of the operator, except for the stent use. Total
tent length was calculated as the sum of the length of each
ingle stent placed to treat LMCA, provided at least one
tent strut was in direct contact with the left main stem at
isual estimation. Angiographic success was defined as
esidual stenosis 30% by visual analysis and the presence
f Thrombolysis In Myocardial Infarction (TIMI) flow
rade 3. All patients were advised to maintain aspirin
able 1. Baseline Characteristics of the Study Population
Variables
Distal
LMCA
Disease
(n  94)
Nondistal
LMCA
Disease
(n  36)
p
Value
ge (yrs)* 65  12 61  12 0.09
ale (%)* 63 72 0.64
ody mass index* 24  4 24  3 0.50
iabetes (%)* 27 22 0.83
ypertension (%)* 63 47 0.41
ypercholesterolemia (%) 65 61 0.87
urrent smokers (%) 19 25 0.64
reatinine (mol/l)* 101  72 89  25 0.32
V ejection fraction (%)* 44  16 46  14 0.42
edical history (%)
Protected left main 14 14 0.99
PCI 31 22 0.53
Myocardial infarction 39 47 0.60
TIA/stroke 10 8 0.99
Heart failure* 15 17 0.99
COPD severe*† 7 5 0.99
Peripheral arterial disease* 22 16 0.63
Carotid artery disease* 9 5 0.71
linical presentation (%)
Stable angina 53 47 0.86
Unstable angina 32 36 0.90
Acute myocardial infarction* 15 17 0.95
Cardiogenic shock at entry* 7 8 0.99
arsonnet score 18  13 14  10 0.048
Parameters included in the Parsonnet classification. †Resulting in functional disabil-
ty, hospitalization, requiring chronic bronchodilator therapy or FEV1 75% of
redicted (10).
COPD  chronic obstructive pulmonary disease; LMCA  left main coronary
rtery disease; LV  left ventricular; PCI  percutaneous coronary intervention;
IA  transient ischemic attack.
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Prognostic Impact of Distal Left Main Disease April 18, 2006:1530–7ifelong, and clopidogrel was prescribed for 6 months in
oth groups.
nd point definitions and clinical follow-up. Distal
MCA disease was defined as significant lumen obstruction
50%) at visual estimation occupying the third distal area
f the LMCA shaft with the entire lesion or part of it either
irectly involving the ostium of the left anterior descending
nd/or circumflex artery or in close contact with at least one
f them. The primary outcome was the occurrence of major
dverse cardiac events, defined as: 1) death, 2) nonfatal
yocardial infarction, or 3) target vessel revascularization.
atients with more than one event have been assigned the
ighest rank event, according to the previous list. All deaths
ere considered to be of cardiac origin unless a noncardiac
rigin was established clinically or at autopsy. Myocardial
nfarction was diagnosed by an increase in the creatine
inase level to more than twice the upper normal limit and
ith an increased creatine kinase-MB fraction. Target
essel revascularization was defined as a repeat intervention
surgical or percutaneous) to treat a luminal stenosis in the
tent or within the adjacent 5-mm segments adjacent to the
tent, including the ostium of the left anterior descending
rtery and/or circumflex artery. Information about in-
ospital outcomes was obtained from an electronic clinical
atabase for patients maintained at our institution and by
eview of hospital records for those discharged to referring
Table 2. Procedural and Angiographic Charact
Variables
Pure LMCA disease (%)
LMCA plus 1-vessel disease (%)
LMCA plus 2-vessel disease (%)
LMCA plus 3-vessel disease (%)
Bifurcation lesion classification (%)
Isolate distal LMCA stenosis
Distal LMCA plus ostial LAD or CFX
Distal LMCA plus both LAD/CFX ostia
Right coronary artery 70% stenosis (%)
Right coronary artery occlusion (%)
Number of implanted stents
Main branch/bifurcation stenting (%)
Culotte/T-stent/Crush/V-stent (%)*
Nominal stent diameter (mm)
Total stent length per patient (mm)
SES/PES (%)
Pre-dilation (%)
Cutting balloon (%)
Rotational atherectomy (%)
Post-dilation (%)
Bigger balloon inflated (mm)
Maximal pressure (atm)
Intravascular ultrasonography (%)
Glycoprotein IIb/IIIa inhibitors (%)
Intra-aortic balloon pump (%)
Left ventricle assist device (%)
Temporary pacing during procedure (%)
*Referred to the total number of patients treated with bifurc
CFX  circumflex artery; LAD  left anterior descending arter
stent; other abbreviations as in Table 1.ospitals (patients were referred from a total of 14 local
ospitals). Post-discharge survival status was obtained from
he Municipal Civil Registries. Data on occurrence of
yocardial infarction (MI) or repeat interventions at
ollow-up were collected by consultation of our institutional
lectronic database, by contacting referring institutions, and
rom all living patients.
uantitative angiographic analysis. Quantitative analyses
f all angiographic data were performed with the use of
dge-detection techniques (CAAS II, Pie Medical, Maas-
richt, the Netherlands). A value of 0 mm was assigned for
he minimum luminal diameter (MLD) in cases of total
cclusion at baseline or follow-up. Binary restenosis was
efined as stenosis of more than 50% of the luminal
iameter in the target lesion. Acute luminal gain was
efined as the MLD after the index procedure minus the
LD at baseline angiography. Late loss was defined as
he MLD immediately after the index procedure minus
he MLD at angiographic follow-up. Net luminal gain
as defined as the difference between MLD at follow-up
nd MLD before the procedure. Quantitative angiographic
easurements of the target lesion were obtained in-stent
nd in-lesion (including the stented segment as well as the
argins 5 mm proximal and distal to the stent).
tatistical analysis. Because the T-SEARCH is an ongo-
ng registry at out institution, the selection of the cohort of
ics of the Study Population
l LMCA
isease
 94)
Nondistal LMCA
Disease
(n  36) p Value
0 19 0.0002
12 25 0.12
20 22 0.82
54 33 0.22
11 – –
40 – –
49 – –
69 64 0.21
17 22 0.63
 0.65 1.22  0.42 0.0003
1/49 89/11 0.005
3/17/13 50/25/25/0 0.29
 0.28 3.26  0.37 0.22
 13 18  13 0.0001
7/63 42/58 0.63
73 70 0.99
3 14 0.05
0 5 0.08
79 75 0.88
 0.46 3.87  0.47 0.025
 3 17.8  3 0.67
20 47 0.045
34 36 0.85
20 18 0.99
2 6 0.32
7 9 0.99
stenting.erist
Dista
D
(n
1.65
5
37/3
3.19
29
3
3.66
18
ation
y; PES  paclitaxel-eluting stent; SES  sirolimus-eluting
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April 18, 2006:1530–7 Prognostic Impact of Distal Left Main Diseaseatients for the present report was based on the following
riteria: a minimum follow-up time of 1 year, and an
xpected major adverse cardiac events (MACE) rate of 10%
n the group of patients without DLMD with a 3 event
ate increase in the DLMD, based on previous findings (1),
ith alpha and beta errors of 5% and 20%, respectively.
Continuous variables are shown as mean  SD and were
ompared using the Student unpaired t test. Categorical
ariables are presented as counts and percentages and are
ompared with the Fisher Exact test. Survival curves were
enerated by the Kaplan-Meier method, and survival among
roups was compared using the log-rank test. Cox propor-
ional hazards models were used to assess risk reduction of
dverse events. Multivariable analysis, considering all vari-
bles reported in Tables 1 and 2 with a p value of 0.10,
as performed to adjust for possible confounders and to
dentify whether DLMD was an independent predictor of
dverse events. Probability was significant at a level of
0.05. All statistical tests were two-tailed. Statistical anal-
sis was performed on Statistica 6.1 (Statsoft Inc., Tulsa,
klahoma).
ESULTS
aseline and procedural characteristics. Baseline and
rocedural characteristics of the patient population, strati-
ed into LMCA disease location, are shown in Tables 1 and
. Patients with DLMD tended to be older and presented
ith an overall higher Parsonnet surgical risk score com-
ared with those without DLMD. Similarly, coronary artery
isease extent, number of stents, and total stent length were
reater and the use of intravascular ultrasound was less than
n DLMD patients. In one patient per group, both present-
ng with acute myocardial infarction, procedural success was
ot obtained because of TIMI flow grade 3 after stenting.
linical outcome based on left main disease location. At
0 days, there was no difference in clinical outcome between
atients with and without DLMD, considering either the
hole population, those receiving an elective intervention,
r those at low surgical risk according to the Parsonnet score
Table 3). Overall, no documented thrombotic stent occlu-
ion occurred in the first 30 days or thereafter.
After a median follow-up of 587 days (range 368 to 1,179
ays; 577 days [range 368 to 1,156 days] in the DLMD
roup vs. 598 days [range 398 to 1,179 days] in the group
ithout DLMD, p  0.56), the cumulative incidence of
ACE (death, MI, or TVR) was significantly higher in
atients with DLMD (30% vs. 11% in those without
LMD; hazard ratio [HR] 3.42, 95% confidence interval
CI] 1.34 to 9.7; p  0.007) (Fig. 1A). The composite
eath/MI was 17% in the DLMD group and 8% in patients
ithout DLMD (HR 2.11, 95% CI 0.45 to 10; p  0.34),
hereas the cumulative incidence of TVR was 13% versus
% in patients with and without DLMD (HR 6, 95% CI
.2 to 29; p  0.02) (Fig. 1B). iIn the elective patient population (106 patients overall, 73
n the DLMD group), the cumulative incidence of MACE
emained greater in the DLMD subgroup (26%) compared
ith those without DLMD (9%; HR 3.59, 95% CI 1.23 to
2.1; p  0.01) (Fig. 1C). The composite of death/MI was
1% in patients with and 6% in those without DLMD (HR
.48, 95% CI 0.7 to 8.5; p 0.35), whereas the need for TVR
as 15% and 3% in the two groups, respectively (HR 6.1, 95%
I 1.6 to 21; p  0.02) (Fig. 1C). Even after excluding
atients receiving protected intervention, the MACE rate
emained higher in patients with compared with those without
LMD (HR 3.1, 95% CI 1.08 to 9.1; p  0.01).
Complex bifurcation stenting was more common in the
LMD subgroup. However, the technique of stent deploy-
ent in itself failed to affect outcome, with a MACE rate of
1% in DLMD patients undergoing stenting of the main
ranch versus 28% in those treated with bifurcation stenting
HR 0.96, 95% CI 0.46 to 1.49; p  0.92).
Patients at high surgical risk according to the Parsonnet
core had a higher MACE rate compared with those at low
isk, confirming previous findings (Fig. 2A).
To explore the additive prognostic value of combining the
natomical location of LMCA disease and surgical risk
tatus, Kaplan-Meier curves were constructed according to
he four combinations generated by having distal or non-
istal LMCA disease and being at high or low surgical risk.
s shown in Figure 2, the cumulative event rate in the
roup of patients affected by nondistal LMCA disease with
ow surgical risk was 10-fold lower (4%) than that observed
able 3. 30-Day Outcomes
Variables
Distal
LMCA
Disease
Nondistal
LMCA
Disease
p
Value*
hole population (n  94) (n  36)
Death, n (%) 7 (7) 3 (8) 0.99
Nonfatal MI, n (%) 4 (4) 0 (0) 0.57
Death or nonfatal MI, n (%) 11 (12) 3 (8) 0.76
TVR, n (%) 0 (0) 1 (3)‡ 0.28
Any event, n (%) 11 (12) 4 (11) 0.99
Stent thrombosis, n (%)† 0 (0) 0 (0) 0.99
lective population (n  71) (n  33)
Death, n (%) 1 (1) 2 (6) 0.25
Nonfatal MI, n (%) 4 (6) 0 (0) 0.32
Death or nonfatal MI, n (%) 4 (6) 2 (6) 0.11
TVR, n (%) 0 (0) 1 (3)‡ 0.31
Any event, n (%) 4 (6) 3 (9) 0.68
Stent thrombosis, n (%)† 0 (0) 0 (0) 0.99
ow-surgical-risk population (n  47) (n  22)
Death, n (%) 0 (0) 0 (0) 0.99
Nonfatal MI, n (%) 1 (2) 0 (0) 0.99
Death or nonfatal MI, n (%) 1 (2) 0 (0) 0.99
TVR, n (%) 0 (0) 1 (4)‡ 0.32
Any event, n (%) 1 (2) 1 (4) 0.54
Stent thrombosis, n (%)† 0 (0) 0 (0) 0.99
By Fisher exact test. †Angiographically documented. ‡In a patient with calcified
stium of the left main coronary artery (LMCA), a residual50% stenosis despite use
f cutting balloon and rotablator justified elective surgical revascularization.
MI  myocardial infarction; TVR  target vessel revascularization.n surgical high-risk patients with DLMD (40%, p  0.002).
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Prognostic Impact of Distal Left Main Disease April 18, 2006:1530–7urgical high-risk status seemed to stratify patients at greater
robability of early events independent of the anatomical
ocation of LMCA disease, whereas DLMD identified pa-
ients at higher risk for late events irrespective of surgical risk.
ultivariable analysis. After adjustment for Parsonnet
isk score (which includes age), the extent of coronary
isease, number of deployed stents, post-procedural mini-
al lumen diameter, bigger balloon inflated, and use of
ntravascular ultrasound at multivariable Cox regression
nalysis, DLMD remained an independent predictor of
ACE (HR 2.79, 95% CI 1.17 to 8.9; p  0.032)
ndependent of surgical risk status (assessed as high risk
ersus low risk; HR 2.18, 95% CI 1.06 to 4.5; p  0.038).
he estimates of these two covariates remained unchanged
f: 1) treatment technique (main branch vs. bifurcation
igure 1. Adverse events in patients treated for distal left main coronary ar
MCA disease (NDLMD). Cumulative risk of major adverse cardiac ev
opulation, and cumulative risk of MACE (C) and TVR (D) in the electtenting) or 2) treatment technique but not number of deployed stents—to check for possible colinearity between
hese two variables—were introduced in the model.
No statistical interaction emerged between the anatomi-
al location of LMCA disease and the surgical risk with
espect to MACE (p  0.3).
uantitative angiographic analysis. Seventy-one patients
n the DLMD group (84% of eligible patients) and 28
atients without DLMD (85% of eligible patients) under-
ent eight-month angiographic follow-up (p  0.99).
uantitative coronary angiography analysis is reported in
able 4. As shown, despite a similar LMCA reference
essel diameter, patients with DLMD location tended to
ave a longer lesion length and a slightly smaller MLD.
n-stent and in-segment acute luminal gain seemed to be
imilar in the two groups, whereas late loss was almost
LMCA) disease (DLMD) as compared with patients treated for nondistal
MACE) (A) and target vessel revascularization (TVR) (B) in the whole
pulation.tery (
ents (ouble in the DLMD group. Thus, in-stent and in-segment
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ompared with those without DLMD.
ISCUSSION
he percutaneous treatment of LMCA disease is a chal-
enging task, with historical event rates often reported to be
nacceptably high (4,13,14). The advent of BMS has not
een regarded as a major breakthrough in the percutaneous
reatment of such lesions (15) because the occurrence of
n-stent restenosis was believed to be associated with fatal-
ties (4,13). Recently, the liberal use of DES to treat LMCA
as been shown to favorably affect outcome compared with
he use of BMS (1–3). However, the rate of major cardio-
ascular events in the DES era remains high in some of the
rst series of patients reported (1,3).
Whether the percutaneous treatment of LMCA should
e strictly reserved for poor surgical candidates or offered
ith less restriction to patients known to be at low risk for
uture MACE remains highly debated (5). Ideally, risk
actors able to differentiate outcomes between those under-
oing catheter-based LMCA treatment and those receiving
urgical revascularization might help in selecting the most
ppropriate revascularization strategy. Anatomical charac-
eristics of the LMCA lesion have great potential in this
egard because they may theoretically influence the percu-
aneous but not the surgical revascularization technique.
ome early observational studies in the BMS era identified
istal location of the disease with respect to LMCA
natomy as a major determinant of restenosis in patients
eceiving percutaneous treatment of the LMCA (6). Simi-
arly, we and other groups have reported that the great
ajority of lesions, which undergo TVR at follow-up, are
igure 2. Cumulative risk of major adverse events in patients with high surg
isk (Parsonnet score15) (A), and in patients at high surgical risk affected
ow surgical risk and DLMD, and low surgical risk and NDLMD (B). *pocated in the distal tract of the LMCA (1,3,16). lThe main finding of our investigation is that the long-
erm outcome of patients undergoing percutaneous treat-
ent for DLMD is significantly worse compared with that
f patients treated for LMCA lesions not located in the
istal tract. Interestingly, this remained true in both elective
nd low-surgical-risk groups. The procedural success rate
long with the short-term (30 days) outcome was remark-
bly similar between the two groups, whereas the difference
etween patients with and without DLMD emerged at
ong-term follow-up, mainly driven by a higher need for
VR in the former group. Despite the lack of statistical
ignificance, the composite of death and nonfatal MI was
onsistently two times higher in the DLMD group, both in
he total cohort of patients (17% vs. 8% in the non-DLMD
roup, p  0.34) and after selection for elective cases only
11% vs. 6.% in the non-DLMD group, p  0.35).
hether these results on death and MI reflect a type II
rror or a chance finding remains unclear.
Our multivariable model, based on all possible confound-
rs of clinical outcome, showed that DLMD is an indepen-
ent predictor of poor outcome in this subset of patients,
ith an adjusted risk for MACE of almost three-fold higher
han that for non-DLMD at long-term follow-up.
To further rule out the possibility that treatment
echnique, more than the anatomical location of the
isease, was responsible for the difference in long-term
utcomes between patients with and without DLMD,
he MACE rate in patients receiving bifurcation stenting
as compared with that in patients undergoing single-
essel stenting in the DLMD subgroup. The MACE rate
as remarkably similar between these two groups of
atients, supporting the hypothesis that the anatomical
isk (Parsonnet score15) as compared with that of patients at low surgical
MD as compared with that of patients at high surgical risk and NDLMD,
.002; †p  0.048; ‡p  0.066. Abbreviations as in Figure 1.ical rocation of the LMCA disease more than the techniques
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Prognostic Impact of Distal Left Main Disease April 18, 2006:1530–7sed to treat it was responsible for the higher overall event rate
n the DLMD group.
In the quantitative angiographic analysis, the late loss was
igher, the acute luminal gain was lower, and the binary
estenosis rate also tended to be higher in the DLMD
roup, which provides a possible mechanistic explanation
or our clinical findings.
Finally, to investigate the prognostic power of DLMD in
elation to surgical risk status, Kaplan-Meier curves were
onstructed according to the four combinations generated
y having distal or nondistal LMCA disease and being at
igh or low surgical risk. Surgical risk status seemed to
tratify patients at a greater probability of events indepen-
ent of the anatomical location of LMCA disease, whereas
LMD identified patients at a higher risk for poor prog-
osis irrespective of surgical risk. Of note is that the surgical
isk status seemed to better risk-stratify patients according
o early events, with survival curves running parallel after the
able 4. Quantitative Coronary Angiography in the Main
tented Branch
Variables
Distal
LMCA
Disease
(n  71)
Nondistal
LMCA
Disease
(n  28)
p
Value
efore procedure
RVD (mm) 3.10  0.59 3.29  0.71 0.52
MLD (mm) 1.18  0.62 1.38  0.65 0.17
Diameter stenosis (%) 61  21 56  17 0.35
Lesion length (mm) 9.8  3.8 8.5  5.3 0.18
fter procedure
In-stent
RVD (mm) 3.00  0.58 3.17  0.56 0.25
MLD (mm) 2.63  0.46 2.89  0.54 0.028
Acute luminal gain (mm)* 1.46  0.7 1.5  0.89 0.80
Diameter stenosis (%) 12  9.5 8.3  8 0.12
In-lesion
RVD (mm) 2.88  0.6 2.99  0.55 0.25
MLD (mm) 2.27  0.51 2.68  0.61 0.0021
Acute luminal gain (mm)* 1.11  0.79 1.28  0.9 0.37
Diameter stenosis (%) 12.87  9.9 10.8  9.3 0.35
ollow-up
In-stent
RVD (mm) 2.99  0.66 3.08  0.58 0.54
MLD (mm) 2.20  0.71 2.65  0.62 0.007
Diameter stenosis (%) 24  22 14  12 0.03
Late loss (mm)† 0.42  48 0.23  0.28 0.01
Net luminal gain (mm)§ 1.03  53 1.27  0.61 0.032
Binary restenosis, no. (%)‡ 9 (13) 0 (0) 0.18
In-lesion
RVD (mm) 2.93  0.63 3.00  0.69 0.69
MLD (mm) 2.01  0.68 2.51  0.62 0.00237
Diameter stenosis (%) 24  22 16  12 0.089
Late loss (mm)† 0.25  0.52 0.15  0.34 0.09
Net luminal gain (mm)§ 0.85  0.58 1.13  0.6 0.02
Binary restenosis, no. (%)‡ 8 (11) 0 (0) 0.19
Difference between MLD after procedure and MLD before procedure. †Difference
etween MLD at follow-up and MLD after procedure. ‡All restenoses were focal
length 10 mm). §Difference between MLD at follow-up and MLD before the
rocedure.
LMCA  left main coronary artery; MLD  minimal lumen diameter; RVD 
eference vessel diameter.rst month of treatment. Conversely, DLMD identifiedatients with a higher event rate at follow-up, with the two
urvival curves diverging at around 180 days after the
rocedure. Interestingly, we failed to identify a statistical
nteraction between surgical risk status and the location of
MCA disease in our patient population, which implies
hat the risk associated with DLMD is additive—not
ultiplicative—with respect to that of being at high surgical
isk status. This further confirms that the two currently used
pproaches for risk stratification, namely surgical risk status
nd anatomical location of the disease, are independent and
ossibly complementary to each other.
As a potential corollary to our findings, the extremely low
vent rate in patients at low surgical risk undergoing LMCA
ntervention for nondistal LMCA disease should not go
nnoticed. This subset of patients with excellent long-term
utcome after catheter-based treatment should be ideally
elected to prospectively test whether percutaneous inter-
ention is a valuable alternative to surgical revascularization
n future trials.
tudy limitations. A limitation of proposing distal loca-
ion of LMCA disease as a risk-stratifying tool lies in the
ecognition that the distal site is the most prevalent site of
isease in LMCA patients undergoing catheter-based in-
ervention in the DES era. Whether this partially reflects
he fact that patients with DLMD are more likely to be at
igher surgical risk or tend to be older, as in our present
eries, and consequently are more likely to undergo percu-
aneous instead of surgical revascularization, remains to be
ddressed.
The results of our study are encouraging, but they cannot
e conclusive. Studies with larger sample sizes and more
rolonged clinical follow-up are clearly in demand to
onfirm our findings and extend our capability to risk-
tratify this challenging subset of patients.
onclusions. The percutaneous treatment of DLMD
merged as a major predictor of poor long-term outcome,
ndependent of the type of procedure (elective versus non-
lective) and the overall surgical risk status. Conversely, the
vent rate after treatment for non-DLMD seemed to be
emarkably low, with an excellent short-term and long-term
rognosis, especially in the low surgical risk population. Our
urrent findings extend the previous knowledge about risk
tratification for patients undergoing catheter-based treat-
ent of LMCA, and may help in identifying the most
ppropriate LMCA population, in which catheter-based
ntervention may be indicated beyond surgical risk status in
he DES era.
eprint requests and correspondence: Dr. Patrick W. Serruys,
horaxcenter, Bd-406, Dr Molewaterplein 40, 3015-GD Rotter-
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